Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis: an Observational Study

NCT07235644 is registered in ClinicalTrials.gov with Uppsala University as lead sponsor.

NCT NCT07235644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07235644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis: an Observational Study
Lead sponsor
Uppsala University
Phase
Observational
Overall status
Active, not recruiting
Start date
January 1, 2025
Completion date
December 30, 2025
Enrollment
184 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ms (multiple sclerosis), multiple sclerosis (ms) - relapsing-remitting, multiple sclerosis (relapsing remitting)